Alzheimer's disease (AD) remains a significant global health challenge, highlighting the need for novel dual inhibitors targeting acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.